News | January 17, 2023
Lonza completes expansion to Solid Form Services Facility at Bend (US) site
New facility is based at Lonza’s Bend, Oregon (US) site, a Center of Excellence for bioavailability enhancement
New facility is based at Lonza’s Bend, Oregon (US) site, a Center of Excellence for bioavailability enhancement
Dolutegravir and Rilpivirine Tablets, 50 mg/25 mg, (RLD Juluca) had estimated annual sales of US $666 million in the US (IQVIA MAT September 2022)
The top 15 Indian pharma players have continued to experience anaemic growth in the US market over the five years ended FY22
APAC to see a reduction in imported surgical robotics
Dr. Reddy’s will manufacture the Active Pharmaceutical Ingredient and finished drug at its facilities approved by USFDA
This will give either party customers access enzyme expertise and assets, resulting in cost-effective, green processing for API manufacturing.
APAC region contributed around 50% of the in-vitro diagnostics market in 2022
OriCiro's synthetic biology and enzyme technologies will support Moderna's expanding portfolio of therapeutics and vaccines
Collaboration to generate and develop therapeutics for oncology and non-oncology conditions
The JUST 100 is the only ranking that recognizes companies doing right by all their stakeholders as defined by the American public.
Subscribe To Our Newsletter & Stay Updated
